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There are great interest and demand for the development of vaccines to prevent and treat diverse microbial
infections. Mucosal vaccines elicit immune protection by stimulating the production of antibodies at mucosal
surfaces and systemic districts. Being positioned in close proximity to a large community of commensal
microbes, the mucosal immune system deploys a heterogeneous population of cells and a complex regula-
tory network to maintain the balance between surveillance and tolerance. A successful mucosal vaccine
relies on leveraging the functions of these immune cells and regulatory components.We review the important
cellular interactions and molecular pathways underlying the induction and regulation of mucosal antibody
responses and discuss their implications on mucosal vaccination.Introduction
Infections caused by many old, emerging, and re-emerging
pathogens, such as Mycobacterium tuberculosis, Vibrio chol-
erae, Aspergillus fumigatus, helminths, coxsackie virus, influ-
enza viruses, rhinovirus, severe acute respiratory syndrome
(SARS) coronavirus, and human immunodeficiency virus (HIV),
pose severe health problems to the world’s population and great
challenges to the realization of Millennium Development Goals
outlined in the United Nations Millennium Declaration. These
health problems are particularly serious to people living in devel-
oping countries and areas of poor hygiene and people with
conditions causing compromised immunity. Although effective
antibiotics are available against most of those bacterial,
fungal, and parasitic pathogens, these drugs are not applicable
for disease prevention and give rise to an insidious trend of
drug resistance after prolonged use. In addition, there are no
approved antiviral drugs highly effective against many viral path-
ogens, such as coxsackie virus, rhinovirus, and SARS coronavi-
rus. Vaccination, which works by stimulating our immune system
to combat infections, appears a promising and much-needed
approach for the treatment and prevention of these diseases.
A common feature of infections caused by these diverse types
of pathogens is that they usually occur or initiate at a mucosal
surface. While ample evidence exists that systemic vaccination
is adequate to offer protection against selected pathogens,
such as polio and influenza viruses (Haan et al., 2001; Herremans
et al., 1999), an increasing number of studies have shown that
induction ofmucosal immunity is required for effective protection
against other important pathogens, such as HIV, human papillo-
mavirus, herpes viruses, Vibrio cholera, and Mycobacterium
species (Belyakov et al., 2001; Chen et al., 2004; Gallichan and
Rosenthal, 1996; Neutra and Kozlowski, 2006; Wang et al.,
2004). In addition to the superior ability of mucosal vaccination
to induce local mucosal immune responses over systemic vacci-
nation (Neutra and Kozlowski, 2006), mucosal vaccination also
offers many logistic and additional immunological advantages
over systemic vaccination. By simply ingesting or inhaling thevaccine, mucosal vaccination does not require injection and
causes less pain and, thus, has a high compliance among
patients of all ages. Simplified manufacturing and storage
methods, as well as independence on trained medical personnel
for delivery, make mucosal vaccines suitable for mass vaccina-
tion programs, especially in developing countries and during
emergency. The mucosal immune system is more accessible
for the induction of an immune response because all mucosal
surfaces can, in principle, act as sites of antigen entry. More
importantly, mucosal vaccination targets specific mucosal
districts and induces ‘‘frontline immunity’’ at the site of pathogen
entry that can prevent the establishment and dissemination of an
infection. In addition, immunization at one mucosal site can
result in antibody secretion systemically, as well as at other
selected mucosal sites (Holmgren and Czerkinsky, 2005).
However, no more than a dozen of mucosal vaccines are
currently approved for human use (Holmgren and Czerkinsky,
2005). This constitutes an embarrassing contrast to the
severe health problem posed by mucosal pathogens and the
many advantages of mucosal vaccination. Such a situation
results largely from the numerous immunological and technolog-
ical challenges confronting the quest of successful mucosal
vaccines. A successful mucosal vaccine should be able to pene-
trate the mucosal barrier at the right mucosal district in a
controlled manner and induce both innate and adaptive immune
responses, such as the activation of dendritic cells (DCs), macro-
phages, epithelial cells (ECs) of the innate immune system, as
well as antigen-specific effector and memory T and B cells of
the adaptive immune system, which cooperate with one another
to achieve optimal potency and duration of protection (Holmgren
and Czerkinsky, 2005). To achieve this goal, adjuvants are
frequently required (see Coffman et al., 2010). Improper mucosal
vaccine formulations can cause poor absorption and limited
bioavailability because of high rates of mucosal enzyme-medi-
ated inactivation and mucosal clearance or may lead to the
delivery of vaccines to improper mucosal districts and targeting
to the wrong mucosal cell types (Holmgren and Czerkinsky,Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 479
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logical balance maintained at mucosal surfaces resulting
from the presence of large numbers of commensal flora, a
successful mucosal vaccine must simultaneously evoke a
mucosal response and avoidmucosal inflammation or tolerance.
Systemic vaccination can deliver a known dose of an antigen into
the body and generate readily measurable humoral and cell-
mediated responses, but the dose of mucosal vaccines that
enters the body is difficult to be measured accurately. The effi-
cacy of mucosal vaccination is also difficult to be determined
because of the difficulties in capturing and quantitating anti-
bodies in mucosal secretions and the technical challenges
in determining the function of diverse mucosal T cell subsets
(Neutra and Kozlowski, 2006).
As mentioned earlier, mucosal immunity involves an intimate
interplay between the innate and adaptive immune systems
through a complex web of cellular and signaling networks.
Thus, a vaccine is expected to achieve optimal responses if it
leverages the interaction between innate and adaptive compo-
nents of the mucosal immune system. This article reviews our
current knowledge of the cellular and molecular pathways
underlying mucosal antibody responses and mucosal homeo-
stasis and discusses the implications of such knowledge on
the design of effective mucosal vaccines.
General Architecture of the Mucosal Immune System
The MALT (mucosa-associated lymphoid tissue) includes the
nasopharynx-associated lymphoid tissue (NALT), the bron-
chus-associated lymphoid tissue (BALT), and the gut-associated
lymphoid tissue (GALT), which comprises Peyer’s patches (PPs)
and isolated lymphoid follicles (ILFs) (Kunisawa et al., 2008).
Humans generally do not have an anatomically well-defined
NALT, except at an early age, but possess oropharyngeal
lymphoid tissues such as pharyngeal, tubal, palatine, and lingual
tonsils (Kunisawa et al., 2008). This set of lymphatic tissues is
called Waldeyer’s ring and may constitute the human equivalent
of mouse NALT (Kiyono and Fukuyama, 2004; Kunisawa et al.,
2008). Conjunctiva-associated lymphoid tissue (CALT), lacrimal
duct-associated lymphoid tissue (LDALT), larynx-associated
lymphoid tissue (LALT), and salivary duct-associated lymphoid
tissue (SDALT) have also been described in humans (Gebert
and Pabst, 1999). All these segments of the MALT comprise
anatomically and functionally distinct inductive andeffector sites.
Inductive sites include mucosa-associated follicles, such as
intestinal PPs, IFLs, and mesenteric lymph nodes, where
antigen-specific T and B cells undergo activation, clonal expan-
sion, and differentiation into T and B effector cells. These cells
migrate from inductive sites to effector sites to carry out their
effector functions. Effector sites are present in all mucosal
districts as a nonorganized lymphoid tissue diffusely distributed
throughout the lamina propria (LP) (Kiyono and Fukuyama,
2004; Kunisawa et al., 2008). Here, cytotoxic T lymphocytes
(CTLs) lyse infected cells, and B cells differentiate into plasma
cells that secrete large amounts of immunoglobulin A (IgA), the
predominant antibody isotype in intestinal secretions together
with IgM. Respiratory and urogenital secretions also contain
IgG and IgD, two antibody isotypes with less defined mucosal
functions. IgA and IgM are transported across ECs by polymeric
Ig receptor (pIgR), whereas IgG is transported across ECs by480 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.neonatal Fc receptor (Rojas and Apodaca, 2002). The antibody
transporter utilized by IgD is unknown (Chen and Cerutti, 2010).
Cells of the Mucosal Immune System
MALT has a general immune architecture resembling that of
systemic lymphoid tissues, including presence of B cell-rich folli-
cles and T cell-rich interfollicular areas. However, MALT also has
several unique anatomic and cellular features. Indeed, GALT and
NALT are provided with efferent, but not afferent, lymphatics
and, therefore, sample exogenous antigens directly from the
mucosal surface (Brandtzaeg et al., 1999). In addition, GALT
and NALT harbor highly heterogeneous populations of immune
cells that establish an intimate interaction with ECs. In this
regard, PPs are capped by a follicle-associated epithelium
equipped with microfold or membranous cells (M cells) special-
ized in antigen sampling. Similar M cells are present in the crypts
of tonsils and adenoids. Owing to their short microvilli, thin
mucus layer, abundant cytoplasmic vesicles, and efficient
transcytosis activity, M cells effectively take up lumenal antigens
and then transfer them to neighboring antigen-presenting cells
(APCs) (Neutra et al., 2001). In general, the MALT contains
a complex network of APCs that differentially modulate mucosal
immune responses. These APCs include multiple DC subsets
that populate specific regions of the MALT and perform distinct
functions (Helft et al., 2010; Iwasaki, 2007a, 2007b; Pulendran,
2006; Varol et al., 2010; for review, see Palucka et al., 2010).
DCs expressing the C-X3-C chemokine receptor 1 (CX3CR1)
are involved in the processing and presentation of antigens to
initiate adaptive T cell responses (Varol et al., 2009), whereas
DCs expressing the aEb7 integrin CD103 condition local CD4
+
T cells to generate T regulatory (Treg) cells, a CD4+ T cell subset
that is pivotal to maintain mucosal immune tolerance and
homeostasis (Coombes et al., 2007; Jaensson et al., 2008).
The phenotype of NALT DCs has not been clearly determined.
Human tonsillar DCs comprise a heterogeneous group of imma-
ture DCs in the reticular epithelium of the crypts and mature DCs
in interfollicular regions (Dieu et al., 1998; Xu et al., 2007, 2008),
but the functional differences among theseDC subsets remain to
be investigated. In addition to DCs, the MALT contains many
other cell types with potential antigen-presenting and regulatory
functions, such as macrophages (Denning et al., 2007; Smythies
et al., 2005). The roles of these cells in the regulation of mucosal
antibody production and immune homeostasis are just begin-
ning to be understood.
Functional Connectivity of the Mucosal Immune System
The mucosal immune system can act independently of the
systemic immune system (Kiyono and Fukuyama, 2004).
Although anatomically separated, different regions of the MALT
are functionally connected in what has been termed the
‘‘common mucosal immune system,’’ which permits T cells and
Bcells activatedbyantigenat one specificmucosal site to appear
as effector T cells andBcells in distantmucosal sites (Kiyono and
Fukuyama, 2004). This functional connectivity is achieved
through the induction of specific sets of mucosal homing recep-
tors during the interaction on T andB cells withmucosal DCs. For
example, oral and intranasal immunization can stimulate effector
T and B cell responses in distant mucosal tissues such as the
intestinal and urogenital tracts (Kiyono et al., 2008). In spite of
Immunity
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entially induces antigen-specific immunity in respiratory and
reproductive tissues, whereas GALT-targeted immunization
predominantly elicits protective responses in gastrointestinal
tissues. Further support for a compartmentalized common
mucosal immune system derives from evidence indicating that
nasal immunization induces IgA-producing B cells to express
C-C chemokine receptor 10 (CCR10) and a4b1 integrin. Binding
of CCR10 and a4b1 to C-C chemokine ligand 28 (CCL28) and
vascular cell adhesionmolecule-1 (VCAM-1), respectively, medi-
ates trafficking of IgA-producing B cells to the respiratory and
genitourinary tracts (Kunkel et al., 2003; Lazarus et al., 2003).
By contrast, oral immunization stimulates IgA-producing B cells
to express CCR9 and CCR10 chemokine receptors, as well as
a4b7 and a4b1 integrins (Kunkel et al., 2003; Lazarus et al.,
2003). Binding of CCR9, CCR10, a4b7, and a4b1 to CCL25,
CCL28, mucosal vascular addressin cell adhesion molecule-1
(MAdCAM-1), and VCAM-1, respectively, permits IgA-producing
B cells to home to the small intestine (Kunkel and Butcher, 2003;
Mora et al., 2006, 2008). These examples highlight the existence
of subtle differences in the ‘‘common mucosal immune system’’
that may result from the exposure of anatomically distinct
mucosal sites to different populations of microorganisms.
Complexity of Mucosal Antibody Responses
It is important for vaccine developers to realize that regions of the
mucosal immune system as different as PPs and LP have enor-
mous potential to complement the function of one another in the
development of mucosal antibody responses and that although
IgA constitutes the predominant class of mucosal antibodies,
multiple layers of antibody responses comprising several anti-
body isotypes are in place to ensure frontline surveillance at
mucosal surfaces. This is reflected by the marked increase
of IgM- and IgG-secreting B cells in the GALT and IgD-, IgG-,
and IgM-secreting B cells in the NALT from subjects with selec-
tive IgA deficiency (Brandtzaeg et al., 1999), which may explain
the frequently asymptomatic nature of this primary immunodefi-
ciency in both humans (Cunningham-Rundles, 2001) and mice
(Mbawuike et al., 1999). It must be also noted that humans
have two IgA1 and IgA2 isotypes with distinct regulation, func-
tion, and anatomic distribution, while mice have only one IgA
isotype (Cerutti, 2008). Underlying these multiple layers of anti-
body responses are the collaborative mechanisms of follicular
and extrafollicular machineries involving T cell-dependent and
T cell-independent pathways of mucosal B cell activation
(Chen et al., 2009; Cong et al., 2009; Fagarasan et al., 2010;
He et al., 2007; Tsuji et al., 2008, 2009). This implies that
amucosal vaccinewill bemore efficient if a response can be initi-
ated by synergistically targeting multiple components of these
complex B cell-activating pathways.
Mechanisms Underlying Mucosal IgA Responses
Mature B cells acquire IgA expression by undergoing a deletional
DNA recombination event called class switch recombination
(CSR) that takes place on the chromosome containing the
recombined Ig heavy (H) chain locus (Cerutti, 2008). In mature
B cells, the IgH locus includes a recombined VHDJH exon, which
encodes the antigen-binding variable region of an antibody, and
multiple sets of constant H chain (CH) exons, which encode theCm, Cd, Cg, Ca, or C3 region of an antibody (Stavnezer et al.,
2008). Each of these CH regions accounts for the effector func-
tions of an antibody, and the Ca region is critical for the transpor-
tation of antibodies across ECs (Cerutti and Rescigno, 2008).
CSR from IgM to IgA involves an exchange of the upstream
donor Cm gene with the downstream acceptor Ca gene and the
deletion of the intervening CH genes (Cerutti, 2008). CSR is
guided by a promoter positioned upstream of a genetic unit
comprising a short intronic (I) exon, a switch (S) region, and
a CH gene (Stavnezer et al., 2008). The selectivity of IgA CSR is
achieved by specific cytokine signals that initiate transcription
at the Ia promoter. Germline transcription allows the CSR
machinery (Stavnezer et al., 2008), which includes the DNA-edit-
ing enzyme activation-induced cytidine deaminase (AID), to
target the Sm and Sa regions to introduce double-strand DNA
breaks (Chaudhuri and Alt, 2004; Muramatsu et al., 2000).
Subsequent joining of these breaks by DNA repair machineries
results in intrachromosomal deletion of the intervening Sm-Sa
sequence and juxtaposition of the downstream Ca gene with
the upstream VHDJH exon encoding the antigen-binding V region
to allow the expression of a full-length IgA. AID also mediates
affinity maturation by introducing high-rate somatic point muta-
tions into the VDJ exons to produce a high-affinity IgA antibody
(Honjo et al., 2002;Muramatsu et al., 2000). IgA class-switched B
cells can further differentiate into plasmablasts or plasma cells
and secrete IgA in the appropriate cytokine environment (Cerutti
and Rescigno, 2008; Macpherson et al., 2008). Understanding
the signals that regulate IgA CSR and production is critical for
the design of effective vaccines to boostmucosal IgA responses.
Follicular Pathways for Mucosal IgA Production
In the GALT, antibody responses are strongly biased toward IgA
and involve activation of follicular B cells by antigen and CD4+
T cells expressing CD40 ligand (CD40L) (Macpherson et al.,
2008). Most of IgA-producing B cells emerge from the germinal
center (GC) of PPs and mesenteric lymph nodes, because these
organized lymphoid structures contain a cellular composition
and cytokine environment conducive to IgA CSR and production
(Figure 1). In particular, PPs have a B:T cell ratio four to six
times higher than that of peripheral lymph nodes (Stevens
et al., 1982). Engagement of CD40 on B cells by CD40L on
CD4+ T cells recruits tumor necrosis factor receptor-associated
factor (TRAF) proteins that activate the nuclear factor-kB (NF-kB)
pathway and induce expression of AID, an essential requirement
for IgA CSR (Cerutti, 2008). The second seemingly essential
requirement for IgA CSR in PPs is transforming growth factor-
b1 (TGF-b1), a cytokine produced by Foxp3+ Treg cells,
CXCR5+ T follicular helper (Tfh) cells, interleukin-10 (IL-10)-
producing T regulatory-1 (Tr1) cells, DCs, stromal cells, B cells,
and perhaps also ECs (Barnes and Powrie, 2009; Cong et al.,
2009; Fagarasan et al., 2001; Fillatreau et al., 2008; Maynard
et al., 2007; Strober, 2009; Tsuji et al., 2009). TGF-b1 plays
a pivotal role in promoting IgA CSR by inducing nuclear translo-
cation of mothers against decapentaplegic (SMAD) proteins,
runt-related transcription factor 3 (RUNX3), and cyclic AMP
response element binding protein (CREB), which cooperatively
initiate germline Ca gene transcription (Cerutti, 2008). Mice
with a B cell-specific deficiency of TGF-b receptor type II and
its downstream signaling proteins show profound deficiency ofImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 481
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Figure 1. Major Cellular Interactions and Regulatory Pathways Involved in IgA Responses to Intestinal Antigens
Mcells fromPPs sample commensal and vaccine antigens from the intestinal lumen and deliver them to subepithelial DCs. Antigen sampling is also carried out by
CX3CR1
+DCs that project dendrites into the intestinal lumen across ECs. These cells release immunoregulatory (TSLP) and IgA-inducing (BAFF and APRIL) mole-
cules upon sensing microbial signatures through TLRs and NLRs. TSLP stimulates the formation of tolerogenic DCs that suppress proinflammatory Th1
responses and induce noninflammatory Treg and Th2 responses by releasing IL-6, IL-10, TGF-b1, and RA. Treg cells may further differentiate into TFH cells, which
together with Treg and perhaps Th2 cells stimulate IgA CSR and production by stimulating naive IgM+IgD+ B cells through CD40L, TGF-b1, IL-6, IL-10, and IL-21.
In the presence of RA, IgA-expressing B cells emerging from mucosal germinal centers acquire expression of gut-homing receptors such as CCR9 and a4b7,
which direct subsequent B cell migration to the intestinal LP through efferent lymphatics, regional mesenteric lymph nodes, and blood circulation. In the LP,
IgA-expressing B cells differentiate into IgA-secreting plasma cells that secrete IgA dimers. Interaction of IgA dimers with the pIgR results into IgA transcytosis
and formation of a secretory IgA (SIgA) complex that binds antigen in the intestinal lumen. The LP also contains IL-10-producing macrophages and BAFF-APRIL-
nitric oxide-producing TipDCswhose development is promoted bymicrobial and epithelial factors such as TSLP. TipDCs andmacrophages would enhance local
IgA production by triggering CSR and stimulating plasma cell survival.
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the GALT (Cazac and Roes, 2000). PPs also contain other cyto-
kines, such as IL-2, IL-4, IL-5, IL-6, and IL-10, which promote the
expansion of IgA class-switched B cells and their differentiation
into IgA-secreting plasma cells (Cerutti, 2008). In addition to PPs,
ILFs constitute another inductive site for IgA CSR and production
(Fagarasan and Honjo, 2003; Fagarasan et al., 2010). The contri-
bution of ILFs to the generation of IgA was demonstrated using
retinoic acid-related orphan receptor-gt (RORgt, encoded by
the Rora gene)-deficient mice, which do not have PPs and ILFs
because of the instrumental role of RORgt+ lymphoid tissue
inducer (LTi) cells in the induction of these structures (Tsuji
et al., 2008). Adoptive transfer to RORgt+ LTi cells into Rora/
mice resulted in the formation of ILFs, but not PPs, and the
appearance of many IgA+ B cells in these ILFs (Tsuji et al.,
2008). Interestingly, activation and IgA CSR in ILFs does not
require help to B cells from CD4+ T cells (Tsuji et al., 2008).
However, ILFs probably contribute only to steady-state IgA
production to commensal flora but have a marginal role in
antigen-specific IgA production in response to mucosal482 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.immunization, as mice treated in utero with soluble TNF decoy
receptor and soluble lymphotoxin b (LTb) decoy receptor, two
compounds that abrogate the formation of PPs and mesenteric
lymph nodes, but not that of ILFs, failed to develop antigen-
specific IgA responses after oral immunization despite having
unaltered intestinal IgA antibodies (Yamamoto et al., 2004). Inter-
estingly, B cells from PPs can undergo IgA CSR and antigen-
specific IgA production without requiring the expression of
a somatically recombined antigen Ig receptor (Casola et al.,
2004), which is usually needed to internalize and present antigen
to CD4+ T cells in the context of a cognate B-T cell interaction.
Instead, B cells from PPs heavily rely on germline gene-encoded
innate antigen receptors known as Toll-like receptors (TLRs) to
mount IgA responses, at least in mice (Casola et al., 2004).
TLRs initiate innate and adaptive immune responses after recog-
nize highly conserved microbial molecular signatures and
provide protection against mucosal infections by enhancing
both IgA CSR and V(D)J somatic hypermutation (Casola and
Rajewsky, 2006; Delgado et al., 2009). These findings highlight
the pivotal role of PPs in oral immunization and indicate the
Immunity
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PPs in order to generate efficient antigen-specific IgA responses
(Neutra and Kozlowski, 2006).
Following activation, CSR and upregulation of gut-homing
receptors such as CCR9, a4b7 integrin, and type 1 sphingo-
sine-1-phosphate (S1P) receptor and downregulation of follic-
ular localization receptors such asCXCR5, IgA-producing B cells
migrate from the inductive site of PPs to the effector site of the
gut LP through efferent lymphatics, regional mesenteric lymph
nodes, and general circulation (Mora and von Andrian, 2008;
Suzuki and Fagarasan, 2009). In the LP, IgA-producing B cells
further differentiate into IgA-secreting plasma cells (Figure 1).
Extrafollicular Pathways for Mucosal IgA Production
Studies in mice and humans have shown that the LP also has all
the necessary cellular and molecular machineries to induce IgA
CSR independently of T cells (Mora and von Andrian, 2008;
Suzuki and Fagarasan, 2009). In the absence of PPs, ILFs, and
mesenteric lymph nodes, intestinal IgA responses can be gener-
ated in the LP. Indeed, mice deficient in inhibitor of DNA binding
2 (Id2) or LTa, which do not have PPs, ILFs, and mesenteric
lymph nodes, retain some antigen-specific IgA plasma cells in
the LP (Eberl and Littman, 2004; Kang et al., 2002). In addition,
protective mucosal antibody responses can be generated by
intranasal immunization with an inactive influenza virus in mice
deficient in CD4+ T cells (Sha et al., 2005). Furthermore, humans
deficient in CD40 or advanced AIDS patients deficient in CD4+
T cells retain intestinal IgA responses in the LP (He et al., 2007;
Xu et al., 2009). These findings have important implications for
the development of mucosal vaccines, especially for people
with a pre-existing condition of immunosuppression, such as
transplant or diabetic patients and HIV-1-infected subjects.
Indeed, the LP contains IgM+ B cells that have migrated from
either the bonemarrow or PPs (Suzuki et al., 2005). These B cells
can undergo differentiation into IgM-secreting plasma cells or
serve as local precursors of IgA- and IgG-producing B cells in
a CD4+ T cell- and CD40L-independent manner (Fagarasan
et al., 2001). T cell-independent antigens initiate IgA CSR by acti-
vating multiple innate immune pathways. Some T cell-indepen-
dent antigens, such as microbial lipopolysaccharide (LPS) and
nucleic acids, activate B cells through TLRs (He et al., 2007;
Pasare and Medzhitov, 2005; Peng, 2005; Xu et al., 2007; Xu
et al., 2008), whereas other T cell-independent antigens, such
as bacterial capsular polysaccharides (CPS), activate B cells
through surface Ig receptors (Mond et al., 1995). DCs, mono-
cytes, neutrophils, basophils, ECs, and stromal cells can release
powerful IgA CSR-inducing factors, such as B cell activating
factor of TNF family (BAFF) and a proliferation-inducing ligand
(APRIL), in response to microbial TLR ligands (Charles et al.,
2010; Chen et al., 2009; Gorelik et al., 2003; He et al., 2007; Litin-
skiy et al., 2002; Scapini et al., 2008; Xu et al., 2007). This places
innate immune cells, epithelial cells, and stromal cells as prom-
inent targets for mucosal vaccination. Some human IgA1 class-
switched B cells can undergo sequential CSR from IgA1 to
IgA2 in the LP under the influence of APRIL expressed by DCs
and ECs. This process is particularly evident in the distal portions
of the intestine, which may account for the greater abundance of
IgA2 found there (He et al., 2007). BAFF and APRIL induce IgA
and IgG CSR by activating germline Ia and Ig transcription andAID expression through NF-kB signaling via receptor transmem-
brane activator and calcium modulator and cyclophylin ligand
interactor (TACI) and the adaptor protein myeloid differentiation
primary response gene 88 (MyD88) (He et al., 2010). When
combined with microbial TLR ligands, BAFF and APRIL are suffi-
cient to induce IgA production in both mouse and human B cells
(He et al., 2007; Tsuji et al., 2008; Xu et al., 2007), suggesting the
existence of an intimate interplay between TACI and TLRs. Our
recent finding that TACI triggers CSR via MyD88 (He et al.,
2010) and the fact that MyD88 is usually associated with TLRs
raises the possibility of signaling integration between TACI and
TLR pathways through MyD88 and suggests that a vaccine
formulation simultaneously activating both pathways could be
superior in boosting mucosal IgA responses in humans.
IgD Production in the Upper Respiratory Mucosa
In humans, one of the most prominent differences between the
respiratory and intestinal mucosal surfaces lies in their immuno-
globulin composition. Unlike mice, humans have a substantial
percentage of IgD-producing B cells in the MALT associated
with the nasal cavities, tonsils, pharynx, salivary glands, and
lacrimal glands, but not in the GALT (Brandtzaeg et al., 1999;
Chen et al., 2009; Chen and Cerutti, 2010). The possibility that
IgD may have an important value in mucosal vaccination is
supported by the observation that the percentage of IgD-
producing B cells in the upper respiratory tract increases to as
much as 60% of all plasmacytes in individuals with selective
IgA deficiency (Brandtzaeg et al., 1999). Similar to humans,
some teleosts have a subset of B cells expressing IgD, but not
IgM, suggesting some evolutionarily conserved immunological
advantages of IgD over IgM (Chen and Cerutti, 2010). Remark-
ably, IgD is the most hypermutated human antibody isotype
and has a long heavy-chain complementarity-determining region
3 (CDR3) (Chen and Cerutti, 2010; Koelsch et al., 2007) that may
form a protruding finger-like structure capable of targeting
recessed neutralizing viral epitopes (Burton et al., 2005; Saphire
et al., 2001). Moreover, IgD can bind to many bacterial virulence
factors and induceB cell-stimulating and antimicrobial programs
in basophils, thereby contributing to mucosal and systemic
antibody production and antimicrobial defense (Chen and
Cerutti, 2010; Chen et al., 2009). Similar to IgA, multiple follicular
and extrafollicular pathways, as well as T cell-dependent and
T cell-independent signals, including CD40L, BAFF, APRIL, as
well as IL-2, IL-15, and IL-21, participate in promoting IgD CSR
and production in mucosal B cells (Chen and Cerutti, 2010;
Chen et al., 2009). The requirement for CD40L, BAFF, APRIL,
and IL-21 in the induction of IgD highlights the importance of
targeting upper aerodigestive mucosal Tfh cells, DCs, and
ECs should mucosal vaccination be aimed at boosting IgD
responses. The dual ability of IgD to bind antigen and amplify
immune activation both systemically and at mucosal sites of
entry may explain why, in some studies, the nasal route is
more advantageous than other routes of vaccine administration
(Holmgren and Czerkinsky, 2005; Chen and Cerutti, 2010).
Mucosal Immunity and Homeostasis: A Tale
of Many Cells
It is important to understand that the mucosal immune system
operates at the forefront of our body’s immune battlefield inImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 483
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deploys multiple types of immune cells organized in phenotypi-
cally and functionally distinct subsets and utilizes an intricate
regulatory signaling network to reinforce mucosal antibody
responses andmaintain a harmonious coexistence with the local
microbiota. Understanding this complex regulatory network is
pivotal to the development of effective mucosal vaccines.
Tfh cells play an important role in promotingmucosal IgA CSR,
IgA production, and homing of IgA-committed B cells tomucosal
sites. Tfh cells in tonsils and PPs produce IL-21 that synergizes
with TGF-b1 to skew CSR toward IgA (Dullaers et al., 2009; Tsuji
et al., 2009). IL-21 also downregulates CXCR5, the chemokine
receptor that promotes follicular localization of B cells, and
upregulates CCR10, the chemokine receptor that facilitates the
migration of IgA class-switched B cells to local mucosal effector
sites (Hieshima et al., 2004; Kunkel et al., 2003). Tfh cells may
derive from Treg cells in PPs upon receiving signals from IL-6,
IL-21, and activated PP B cells (Tsuji et al., 2009). Therefore,
one prediction is that mucosal vaccines should robustly promote
the generation of Tfh cells from Treg cells to induce protective
IgA production and concurrently avoid mucosal tolerance.
Besides Tfh cells, important regulation of mucosal follicular
antibody responses is also carried out by ECs, DCs, macro-
phages, Treg cells, Tr1-like cells, granulocytes, NK cells, as
well as B cells themselves. ECs as gatekeepers of the mucosa
release myriad factors in response to the commensal microbes
present in the lumen, probably by sensing these microbes
through innate immune receptors, such as TLRs and intracellular
Nod-like receptors (NLRs) (Abreu, 2010; Hooper and Macpher-
son, 2010). Among such important factors are BAFF, APRIL,
secretory leukocyte protease inhibitor (SLPI), and thymic stromal
lymphopoietin (TSLP). Epithelial BAFF and APRIL promote T cell-
independent IgACSR and plasma cell survival, while SLPI serves
as a homeostatic regulator to attenuate BAFF signaling in B cells
(He et al., 2007; Xu et al., 2007). TSLP stimulates DCs to produce
more BAFF and APRIL (He et al., 2007; Xu et al., 2007) and to
skew T cell differentiation toward the Th2 cell direction through
repression of IL-12 (Rimoldi et al., 2005; Zaph et al., 2007) and
the induction of OX40 ligand (OX40L) (Ito et al., 2005), engen-
dering a Th2 cell-dominated environment in PPs helpful for the
production of IgA. A subset of mucosal DCs express CD103
(also called aE integrin), which may bind the epithelial adhesion
molecule E-cadherin to facilitate DC conditioning by ECs
(Strober, 2009). TSLP-conditioned CD103+ DCs also produce
TGF-b1 and IL-10 (Li and Flavell, 2008). In addition to facilitating
IgA CSR, TGF-b1 and IL-10 cooperate with other DC-derived
factors, such as retinoic acid (RA) and indoleamine-2,3-dioxyge-
nase (IDO), to induce the development of Treg cells and
suppress the development of proinflammatory Th17 cells
(Coombes et al., 2007; Matteoli et al., 2010; Mucida et al.,
2007). Furthermore, TGF-b1 and IL-10 cooperate with IL-27 to
induce the development of Tr1-like cells (Barnes and Powrie,
2009). Human intestinal macrophages do not produce proin-
flammatory cytokines in response to inflammatory stimuli
(Smythies et al., 2005), and mouse LP macrophages promote
the development of Treg cells (Denning et al., 2007). All these
mucosal cell types are important to maintain a noninflammatory
environment and prevent harmful immune responses against
commensals under physiological conditions. As mentioned484 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.earlier, Treg cells, Treg-derived Tfh cells, and Tr1 cells are also
important sources of IgA-inducing signals such as TGF-b1,
IL-10, and IL-21 (Cong et al., 2009; Tsuji et al., 2009). Conversely,
IgA-producing B cells and their precursors may enhance the
generation of Treg cells and Tr1 (or Tr1-like) cells by releasing
IL-10 and TGF-b1 (Asseman et al., 1999; Cerutti and Rescigno,
2008; Fillatreau et al., 2008; Mizoguchi et al., 2002). Of note,
TGF-b1 is produced in a latent form and requires either proteo-
lytic cleavage of a proregion by matrix metalloproteinases
(MMPs) or a conformational change by binding to certain cell-
surface receptors in order to convert an inactive TGF-b1
precursor into active TGF-b1 (Taylor, 2009). Unlike DCs from
systemic lymph nodes, mucosal DCs uniquely express high
levels of MMP9 and MMP13 and can activate TGF-b1 with
high efficiency (Tsuji et al., 2008). In addition to TGF-b1, mucosal
DCs release RA, which cooperates with IL-5 and IL-6 to enhance
IgA secretion (Iwata et al., 2004; Mora et al., 2006). Mucosal DCs
would further augment IgA production through nitric oxide. In
mice, the intestinal mucosa contains a subset of DCs called
TipDCs that express TNF and inducible nitric oxide synthase
(iNOS) and release large amounts of nitric oxide after recognizing
commensal bacteria through TLRs (Tezuka et al., 2007). Nitric
oxide enhances IgA CSR and production by upregulating TGF-
bRII expression on PP B cells and by inducing DC expression
of BAFF and APRIL through unknown mechanisms (Tezuka
et al., 2007). As for mucosal NK and NKT cells, the role of these
innate cell types in mucosal immunity is not well understood, but
several studies show that they contribute to mucosal homeo-
stasis by releasing IL-22, a cytokine that enhances the survival,
proliferation, and antimicrobial activity of ECs (Colonna, 2009;
Satoh-Takayama et al., 2008; Vivier et al., 2009; Zenewicz
et al., 2008). Given the broad role of IL-22 in mucosal homeo-
stasis, it is conceivable that this cytokine also augments the
production of IgA-inducing factors by ECs.
Food for Thought: Mucosal Immune Regulation
by Vitamin A
As discussed above, many regulatory DC subsets in the GALT
produce RA, a metabolic derivative of vitamin A found in food.
Indeed, the ability to synthesize RA is not limited to GALT DCs,
but seems to be a broad phenomenon found in many mucosal
immune cells, such as LP CD11b+ macrophages (Denning
et al., 2007), mesenteric lymph node CD103+ DCs (Coombes
et al., 2007), PP DCs (Iwata et al., 2004), LP CD103+ DCs
(Uematsu et al., 2008), LP TipDCs (Tezuka et al., 2007), ECs
(Iwata et al., 2004), mast cells and basophils (Spiegl et al.,
2008). By promoting IgA CSR, plasma cell differentiation and
Treg cell development, RA appears to be a central regulator of
intestinal immunity and homeostasis. Moreover, RA is a central
regulator of T cell and B cell trafficking toward the effector site
of the intestinal LP. RA induces the expression of gut homing
receptors such as a4b7 integrin and CCR9 on CD4
+ T cells (Iwata
et al., 2004),CD8+T cells (Iwata et al., 2004), CD8a+ intraepithelial
lymphocytes (IELs) (Iwata et al., 2004), Treg cells (Benson et al.,
2007), and B cells (Mora et al., 2006; Tezuka et al., 2007). Gut
homing is achieved by a4b7 integrin binding to MAdCAM-1
expressed on endothelial cells at the post-capillary venules in
intestinal tissues, and CCR9 binding to the chemokine CCL25
released by ECs in the small intestine (Iwata et al., 2004; Mora
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reactions that culminate in a final irreversible step catalyzed by
retinal dehydrogenase 1 (RALDH1) and RALDH2. Peroxisome
proliferator-activated receptor g (PPARg) agonist, IL-4 as well
as bacterial flagellin, a ligand of TLR5, have been shown to acti-
vate RALDH2 expression in DCs (Elgueta et al., 2008; Szatmari
et al., 2006; Uematsu et al., 2008). Low amounts of these signals
might be involved in themaintenance of basal RALDHexpression
and RA production in GALT. As RA is a diet derivative, mucosal
vaccination strategies that encompass stimulation of RAproduc-
tion through dietary supplementation of vitamin A as well as
induction of RALDH expression seem appealing and should be
explored, particularly for vaccination trials in developing coun-
tries where vitamin A deficiency is common.
Toll-Like Receptors: Swords with a Toll
A great number of vaccination studies in animal models and
humans have demonstrated the benefits of taking advantage
of TLR signaling system to boost the efficacy of mucosal
vaccines (Mbow et al., 2010). As discussed earlier, TLRs are
involved in the recognition of microbial molecular structures
and are expressed bymultiple cells types in themucosal immune
system, such as ECs, DCs, T cells, and B cells. By sensing prod-
ucts of commensal and pathogenic microorganisms, they
induce the expression of critical regulatory factors to contribute
to mucosal defense and homeostasis. In the presence of micro-
bial TLR ligands, intestinal ECs express antimicrobial factors
such as RegIIIg (Cash et al., 2006), B cell-activating factors
such as BAFF and APRIL (He et al., 2007; Xu et al., 2007), and
immunoregulatory factors such as TSLP (Liu et al., 2007),
whereas MALT DCs express iNOS and produce nitric oxide
(Tezuka et al., 2007). LP TLR5+ DCs express RALDH2 and
produce RA in response to flagellin stimulation (Uematsu et al.,
2008). B cells express TLRs and stimulation with a variety of
TLR ligands triggers B cell proliferation, differentiation into anti-
body secreting cells, antigen presentation, cytokine secretion,
and CSR (Avalos et al., 2010; Lanzavecchia and Sallusto,
2007). The importance of this pathway in vaccination is exempli-
fied by a recent study showing the critical requirement of pro-
viding TLR stimulation directly to B cells in order for a formalin-
inactivated respiratory syncytial virus vaccine to induce affinity
maturation and confer protection (Delgado et al., 2009).
However, the benefits of targeting TLRs in mucosal vaccina-
tion come at a price. Administration of TLR ligands may cause
inflammation and autoimmune diseases, especially after long-
term stimulation (Avalos et al., 2010; Israeli et al., 2009; Mullick
et al., 2005). Certain TLR ligands may play a pathogenic role in
tumorigenesis. Existing neoplastic processes may divert TLR
signaling in tumors and facilitate their survival or immune evasion
(Huang et al., 2005; Rakoff-Nahoum andMedzhitov, 2007; Wang
et al., 2003). Imprudent therapeutic targeting of TLRs in mucosal
vaccination should be cautioned, and circumvention of these
potential adverse effects will rely on a thorough understanding
of the responses of different mucosal immune cell types to
various TLR ligand stimulations.
Advantages to Target Mucosal Antibody Responses
Antibody responses initiated at mucosal inductive sites exhibit
their protective function by myriad mechanisms, some of whichare distinct from their systemically initiated counterparts.
Mucosal antibody responses offer a critical step for the protec-
tion of the host by inhibiting the very first step of microbial path-
ogenesis, i.e., microbial adherence to mucosal ECs (Cerutti and
Rescigno, 2008). Mucosal antibodies can also inhibit the activity
of many detrimental microbial enzymes and toxins in the lumen
and neutralizemucosal viruses inside ECs (Cerutti andRescigno,
2008). For invasive pathogens that have breached the epithelial
barrier, mucosal IgG can mediate opsonization and internaliza-
tion of the pathogens by phagocytes, which in turn leads to the
activation of phagocytes and killing of the pathogen or presenta-
tion of pathogen-derived antigens that activates multiple types
of mucosal effector T cells, such as Th17 cells, gd T cells, and
CD8+ CTL cells, to promote pathogen containment or clearance
(Cerutti and Rescigno, 2008). Mucosal antibodies, such as IgG
and IgA, can promote antibody-dependent cell-mediated cyto-
toxicity (ADCC) by NK cells, neutrophils, and eosinophils to
lyse infected cells (Nimmerjahn and Ravetch, 2006). IgD can
recruit basophils to the aerodigestive mucosa and activate their
antimicrobial and B cell-stimulating responses to directly partic-
ipate in frontline antimicrobial defense (Chen et al., 2009).
There are some added advantages for vaccines to boost
mucosal IgA responses. IgA can mediate apical-to-basolateral
retrotranscytosis of antigens across M cells via an unknown
receptor or across duodenal epithelial cells via the transferring
receptor (also known as CD71), thereby enabling controlled
entry of specific antigens to initiate mucosal immune responses
(Cerutti and Rescigno, 2008). This retrotranscytosis process
can deliver intact antigens to the basolateral side of ECs
(Phalipon and Corthe´sy, 2003). Conversely, IgA can transport
invasive pathogens that have breached the epithelial barrier
back to the lumen for elimination through pIgR-mediated baso-
lateral-to-apical transcytosis (Kaetzel et al., 1991). This process
would limit the amount of immune complexes available in the LP,
thereby avoiding unnecessary inflammatory mucosal responses
in situations where there is no severe infection. Vaccinations
targeting mucosal IgA responses have the additional advantage
of triggering systemic production of monomeric IgA (Macpher-
son et al., 2008). This IgA promotes immune protection without
causing detrimental systemic inflammation by removing
invading pathogens through a noninflammatory FcaRI receptor
expressed on the surface of phagocytes, including neutrophils
(Cerutti and Rescigno, 2008; Pasquier et al., 2005). Finally,
recent evidence indicates that secretory IgA ‘‘appeases’’ the
mucosal immune system that is in close contact with heavy
indigenous microbial loads by restraining commensal flora-
induced activation of the host oxidative system (Peterson
et al., 2007).
Mucosal Immune Dynamics and Implications
for Vaccine Design
Recent studies on intestinal immune responses to commensal
flora have yielded important insights into the dynamics of
mucosal antibody responses and revealed novel differences
from systemic antibody responses. Commensal flora is known
to orchestrate the postnatal maturation of mucosal immune
systems (Artis, 2008; Macpherson and Uhr, 2004). Using
a controlled, reversible intestine colonization system, intestinal
IgA responses were shown to be directed against only a fewImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 485
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Reviewmajor commensal microbial species at a given time (Cerutti,
2010; Hapfelmeier et al., 2010; Jiang et al., 2001; Suzuki
et al., 2004), similar to intestinal T cell responses, which are
mainly directed against major segmented filamentous bacteria
species (Gaboriau-Routhiau et al., 2009; Ivanov et al., 2008).
Furthermore, intestinal IgA responses have a high threshold of
108–109 bacteria, below which there is no elicitation of IgA
production. It lacks classical memory prime-boost features
and displays constant attrition, where subsequent challenges
with different antigens diminish the response to previous anti-
genic challenges. This deviates substantially from classical
systemic immune memory paradigms. Therefore, intestinal IgA
responses have a built-in ‘‘algorithm’’ for total strength control
that constantly adapts intestinal IgA to the current microbiota.
Such ‘‘mucosal immunological logic’’ is conceivable considering
the fact that the most abundant microbial species have a higher
chance of breaching the epithelial barrier. Therefore, steady-
state IgA should predominantly target those species to avoid
potentially wasteful over-diversified responses. Because of
the great abundance of commensal bacteria, intestinal IgA
responses also involve a high antigenic threshold. All these
features highlight the importance of the integrity of the epithelial
barrier. Indeed, mucosal inflammation, clonal exhaustion, and
immunological paralysis could ensue should these abundant
commensal species breach the epithelia in overwhelming
amounts (Halliday, 1971; Mitchison, 1964). IgA limits these
potentially lethal outcomes by tightly controlling the amount of
antigen input across ECs. If we assume that mucosal immune
responses to antigens from pathogens and vaccines follow
a similar set of principles, induction of long-lasting protective
IgA responses would require the use of vaccination strategies
that ensure prolonged supply of antigens and sustained stimula-
tion of intestinal B cells. These strategies could include embed-
ding appropriate immunogens in stable components of the
microbiota, edible probiotic bacteria, or genetically modified
food, such as transgenic plants (Tokuhara et al., 2010). However,
caution must be exercised in vaccine design and evaluation to
avoid the induction of mucosal tolerance as a result of prolonged
antigenic stimulation.
Yin and Yang of Mucosal Vaccination: Immunity
versus Tolerance
As discussed earlier, the induction of mucosal IgA responses
involves multiple regulatory mechanisms that also function to
promote mucosal and systemic T cell hyporesponsiveness by
inducing Treg cell development. Indeed, administration of anti-
gens to human gastrointestinal or respiratory tracts can induce
a profound reduction in cellular immunity, evidenced by dimin-
ished delayed type hypersensitivity reactions, reduced T cell
proliferation, and increased T cell secretion of immunosuppres-
sive cytokines, without altering humoral immunity (Mayer and
Shao, 2004; Mowat, 2003). This phenomenon, termed oral toler-
ance, remains a challenge for mucosal vaccine development. In
the past, mucosal immunization protocols eliciting concomitant
induction of B cell and Treg cell responses were exploited to
develop antibody-mediated protection against poliovirus and
influenza virus (Bergerot et al., 1997; Phipps et al., 2003; Tamura
et al., 1997; Tarkowski et al., 1999). Similar approaches could be
harnessed to dampen inflammatory systemic and mucosal486 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.responses present in disorders such as asthma, uveitis, dia-
betes, and rheumatoid arthritis (Mayer and Shao, 2004), but
may be a hurdle for mucosal vaccination against pathogens
requiring the development of humoral and cellular immune
responses, both systemically and at mucosal sites of entry
(Figure 2). In such cases, an approach that combines mucosal
and systemic vaccination or one that targets additional immune
cell types with less regulatory functions but TH1- or CTL-acti-
vating abilities, such as neutrophils (Appelberg, 2007) and
CD14+CD33+ LP mononuclear phagocytes (Kamada et al.,
2008), may be effective.
Summary and Future Challenges
Studies based on various mouse models, human diseases, and
successful examples of mucosal vaccines have clearly demon-
strated the pivotal role of mucosal antibodies in frontline immune
protection and their instructive functions in systemic immunity.
In spite of recent advances in structural biology and nanotech-
nology improving vaccine delivery (Chadwick et al., 2010)
and additional advances in genome sequencing technology
fostering reverse vaccinology and antigen discovery (see review
by Sette and Rappuoli, 2010), the development of effective
mucosal vaccines and adjuvants is still hampered by our inability
to fully understand the intricate regulatory networks governing
mucosal immunity. A better understanding of these networks
would permit the elicitation of sustained protective immune
responses in both mucosal and systemic districts without
causing excessive immune activation or inappropriate immune
tolerance. Our current knowledge of the intricacies character-
izing the mucosal immune system may only allow us to have
a glimpse of the tip of the iceberg. The lineage and functional
heterogeneity and plasticity of the mucosal immune cell types
reviewed here may already seem exceedingly confusing (Geiss-
mann et al., 2010), yet more mucosal cell types with key regula-
tory functions are being described (Buonocore et al., 2010;
Dardalhon et al., 2008; Neill et al., 2010; Saenz et al., 2010;
Siddiqui et al., 2010; Veldhoen et al., 2008). In addition, the func-
tions of old cell types and molecules abundant in mucosal
districts, such as eosinophils, mast cells, mucins, secretory
component, antimicrobial peptides, as well as diet-derived
molecules, remain poorly understood. While trying to take
advantage of these regulatory mechanisms for vaccination, it
is also important to bear in mind that some sophisticated path-
ogens hitch a ride on certain regulatory mechanisms to establish
or reinforce infection (Fontenot et al., 2009). In addition, mucosal
IgA responses induced by harnessing these regulatory mecha-
nisms can result in a self-limiting situation because of the shield-
ing of inductive lymphoid structures such as PPs (Brandtzaeg
and Johansen, 2007).
There are several more points for immunologists and vaccine
developers to ponder. Although mucosal immunization elicits
mucosal and systemic antibody responses, its impact on cell-
mediated immunity, particularly the induction of systemic and
mucosal CTL responses, has not been adequately investigated.
Such studies are particularly relevant to the design of prophy-
lactic vaccines against pathogens such as HIV, which might
take advantage of the undesirable effect of diminishing beneficial
CTL responses to spread with higher speed throughout the
body. Furthermore, the mucosal immune system declines as
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Figure 2. Parallel Regulatory Mechanisms
for Induction of Mucosal Immunity and
Tolerance
Intestinal ECs release immune regulatory factors,
such as TSLP, RA, and TGF-b1, upon sensing anti-
gens from the lumen. These immune mediators
condition DCs to generate CD103+ DCs and
TipDCs. Such regulatory DCs produce more
immune regulatory factors, such as TGF-b1, RA,
IL-10, and IL-27, which reinforce mucosal homeo-
stasis and tolerance by promoting the develop-
ment of IgA responses and regulatory T cell
responses, including Treg and Tr1 responses.
Treg and Tr1 cells suppressmucosal and systemic
responses by Th1 cells, Th17 cells, and CTLs. Such
a situation may represent a challenge for mucosal
vaccines aimed at eliciting mucosal and systemic
T cell-mediated immunity.
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Reviewthe subject becomes older, a phenomenon called immunose-
nescence, with GALT declining at an earlier age than NALT, as
evidenced by a reduction in GALT mass, intestinal antigen-
specific IgA responses, and defective oral tolerance induction
(Fujihashi and Kiyono, 2009). This may necessitate that vaccina-
tion strategies be different for older people compared to younger
people and suggests that the nasal route may be more desirable
for effective mucosal vaccination in the elderly. The mucosal
immune system also changes under certain physiological and
pathological conditions, such as female menstrual cycles and
metabolic syndromes (Black et al., 2000; Vijay-Kumar et al.,
2010), which can affect the outcome of mucosal vaccination.
Solving these various issues are necessary prerequisites before
we can reach the milestone of ‘‘vaccine for all’’ and truly realize
the aspirations set forth in the Millennium Development Goals.ACKNOWLEDGMENTS
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